Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 8/2011

01-08-2011 | Short Communication

High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series

Authors: Franziska Lezius, Christine Adrion, Ulrich Mansmann, Klaus Jahn, Michael Strupp

Published in: European Archives of Oto-Rhino-Laryngology | Issue 8/2011

Login to get access

Abstract

The objective of this study was to evaluate the clinical benefit and the side effects of high dosages of betahistine dihydrochloride (288–480 mg/day) in patients with severe Menière’s disease (MD). In this case series 11 patients with MD who had not responded sufficiently to a dosage of 144 mg/day of betahistine dihydrochloride were treated on an individual basis with daily dosages between 288 and 480 mg of betahistine dihydrochloride. The number of attacks per month and the side effects were monitored. Non-parametric tests were used for statistical analysis. As a result, the frequency and the severity of vertigo were significantly reduced in all patients. The side effects were mild, self-limiting, and did not require any change in the treatment strategy. Despite the considerable limitations of an observational study—in particular in MD—high dosages of betahistine dihydrochloride between 288 and 480 mg/day seem to be effective in patients who do not sufficiently respond to lower dosages. Moreover, such dosages are well tolerated.
Literature
1.
Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg. (1995) 113(3):181–185
2.
Merchant SN, Adams JC, Nadol JB Jr (2005) Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol 26(1):74–81PubMedCrossRef
3.
Dieterich M, Brandt T (1999) Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 246(10):883–892PubMedCrossRef
4.
Guilemany JM, Martinez P, Prades E, Sanudo I, De Espana R, Cuchi A (2004) Clinical and epidemiological study of vertigo at an outpatient clinic. Acta Otolaryngol 124(1):49–52PubMedCrossRef
5.
Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 56(4):436–441PubMed
6.
van Cruijsen N, Jaspers JP, van de Wiel HB, Wit HP, Albers FW (2006) Psychological assessment of patients with Meniere’s disease. Int J Audiol 45(9):496–502PubMedCrossRef
7.
Eckhardt-Henn A, Best C, Bense S, Breuer P, Diener G, Tschan R et al (2008) Psychiatric comorbidity in different organic vertigo syndromes. J Neurol 255(3):420–428PubMedCrossRef
8.
9.
Strupp M, Hupert D, Frenzel C, Wagner J, Hahn A, Jahn K et al (2008) Long-term prophylactic treatment of attacks of vertigo in Meniere’s disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol 128(5):520–524PubMedCrossRef
10.
Jeck-Thole S, Wagner W (2006) Betahistine: a retrospective synopsis of safety data. Drug Saf 29(11):1049–1059PubMedCrossRef
11.
James AL, Burton MJ (2001) Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev (1): CD001873
Metadata
Title
High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series
Authors
Franziska Lezius
Christine Adrion
Ulrich Mansmann
Klaus Jahn
Michael Strupp
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
European Archives of Oto-Rhino-Laryngology / Issue 8/2011
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-011-1647-2

Other articles of this Issue 8/2011

European Archives of Oto-Rhino-Laryngology 8/2011 Go to the issue

Head and Neck

Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases

Otology

Clinical characteristics of granular myringitis treated with castellani solution

Laryngology

Double probe pH-monitoring findings in patients with benign lesions of the true vocal folds: comparison with typical GERD and the effect of smoking

Head and Neck

Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract

Rhinology

Paranasal sinuses computed tomography in the initial evaluation of patients with suspected invasive fungal rhinosinusitis

Letter to the Editor

Comment on “Vestibular-evoked myogenic potentials eliciting: an overview”